Search Result

Results for "

urinary excretion

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bacterial (1) Drug Metabolite (1) Endogenous Metabolite (10) Isotope-Labeled Compounds (1) Na+/Ca2+ Exchanger (3) Prostaglandin Receptor (1) SGLT (1) Small Interfering RNA (siRNA) (1)
By Research Areas:	Cardiovascular Disease (3) Endocrinology (1) Inflammation/Immunology (3) Metabolic Disease (12) Neurological Disease (3)
Oligonucleotides:	siRNAs (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113409

3-Hydroxyisovaleric acid	Endogenous Metabolite	Metabolic Disease
3-Hydroxyisovaleric acid is a normal endogenous metabolite excreted in the urine. The urinary excretion of 3-hydroxyisovaleric acid is early and sensitive indicator of biotin deficiency .

HY-76199

trans-4-Hydroxycyclohexanecarboxylic acid	Bacterial	Metabolic Disease
trans-4-Hydroxycyclohexanecarboxylic acid is a substrate for cyclohexanecarboxylic acid production. trans-4-Hydroxycyclohexanecarboxylic acid is the by-product of intestinal bacterial metabolism via urinary excretion .

HY-132613

Lumasiran sodium	Small Interfering RNA (siRNA)	Metabolic Disease
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .

HY-113420

11-Dehydro-thromboxane B2	Endogenous Metabolite	Metabolic Disease
11-Dehydro-thromboxane B2 is a platelet hemagglutinin. Thromboxane inhibition was assessed by urinary excretion levels of 11-Dehydro-thromboxane B2. 11-Dehydro-thromboxane B2 can be used in the study of atherosclerotic thrombosis .

HY-113377A

L-Glyceric acid sodium	Endogenous Metabolite	Metabolic Disease
L-Glyceric acid sodium is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid sodium can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid sodium excretion to distinguish PH1 from PH2 .

HY-137339

Amitriptyline N-β-D-glucuronide	Others	Others
Amitriptyline N-β-D-glucuronide is an ammonium glucuronide and an urinary excretion metabolite of amitriptyline .

HY-B2153

Tetraethylenepentamine pentahydrochloride	Others	Metabolic Disease
Tetraethylenepentamine pentahydrochloride is an effective chelator in increasing the urinary excretion of copper .

HY-W509797

5-(3',4'-Dihydroxyphenyl)-γ-valerolactone	Drug Metabolite	Inflammation/Immunology
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone is a gut microbiota metabolite of (-)-Epicatechin (HY-N0001). 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone exhibits antioxidant activity .

HY-126816

Atrazine mercapturate	Endogenous Metabolite	Others
Atrazine mercapturate is a metabolite of herbicide Atrazine (HY-N7091), which is detectable in urinary excretion. Atrazine mercapturate serve as an unambiguous confirmation of human exposure to Atrazine .

HY-113377

L-Glyceric acid	Endogenous Metabolite	Metabolic Disease
L-Glyceric acid is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid excretion to distinguish PH1 from PH2 .

HY-113409R

3-Hydroxyisovaleric acid (Standard)	Endogenous Metabolite	Metabolic Disease
3-Hydroxyisovaleric acid (Standard) is the analytical standard of 3-Hydroxyisovaleric acid. This product is used for research and analytical applications. 3-Hydroxyisovaleric acid is a normal endogenous metabolite excreted in urine. The urinary excretion of 3-Hydroxyisovaleric acid serves as an early and sensitive indicator of biotin deficiency .

HY-113329

Guanidinoethyl sulfonate Taurocyamine	Endogenous Metabolite	Metabolic Disease
Guanidinoethyl sulfonate (Taurocyamine), a transport antagonist of taurine, induces much urinary taurine excretion with a resulting decrease in the tissue taurine content and readily produces taurine-deficient fetal rats in pregnant rats . Guanidinoethyl sulfonate, a structural analogue of taurine, acts as a competitive inhibitor of taurine transport .

HY-113465

Leukotriene E4 LTE4	Endogenous Metabolite	Inflammation/Immunology
Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.

HY-113465S

Leukotriene E4-d5 LTE4-d₅	Endogenous Metabolite	Inflammation/Immunology
Leukotriene E4-d₅ is the deuterium labeled Leukotriene E4. Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.

HY-122613

YM543 free base	SGLT	Metabolic Disease
YM543 free base is a potent and orally active sodium-glucose cotransporter (SGLT) 2 inhibitor. YM543 free base reduces blood glucose levels. YM543 free base can be used in research of diabetes .

HY-113420S2

11-Dehydro-thromboxane B2-13C5	Endogenous Metabolite Isotope-Labeled Compounds	Metabolic Disease
11-Dehydro-thromboxane B2- ¹³C₅ is ¹³C labeled 11-Dehydro-thromboxane B2 (HY-113420). 11-Dehydro-thromboxane B2 is a platelet hemagglutinin. Thromboxane inhibition was assessed by urinary excretion levels of 11-Dehydro-thromboxane B2. 11-Dehydro-thromboxane B2 can be used in the study of atherosclerotic thrombosis .

HY-136182

YM-244769 dihydrochloride	Na+/Ca2+ Exchanger	Cardiovascular Disease Neurological Disease
YM-244769 dihydrochloride is a potent, selective and orally active Na ⁺/Ca ²⁺ exchanger (NCX) inhibitor. YM-244769 dihydrochloride preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca ²⁺ entry mode), with IC₅₀s of 18 nM and 50 nM, respectively. YM-244769 dihydrochloride efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 dihydrochloride can also increase urine volume and urinary excretion of electrolytes in mice .

HY-136182A

YM-244769	Na+/Ca2+ Exchanger	Cardiovascular Disease Neurological Disease
YM-244769 is a potent, selective and orally active Na ⁺/Ca ²⁺ exchanger (NCX) inhibitor. YM-244769 preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca ²⁺ entry mode), with IC₅₀s of 18 nM and 50 nM, respectively. YM-244769 efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 can also increase urine volume and urinary excretion of electrolytes in mice .

HY-107659

YM-244769 hydrochloride	Na+/Ca2+ Exchanger	Cardiovascular Disease Neurological Disease
YM-244769 hydrochloride is a potent, selective and orally active Na ⁺/Ca ²⁺ exchanger (NCX) inhibitor. YM-244769 hydrochloride preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca ²⁺ entry mode), with IC₅₀s of 18 nM and 50 nM, respectively. YM-244769 hydrochloride efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 hydrochloride can also increase urine volume and urinary excretion of electrolytes in mice .

HY-129397

2,3-Dinor-11beta-prostaglandin F2alpha BPG; 2,3-Dinor-11β-PGF2α; 2,3-dinor-11-epi PGF2α	Prostaglandin Receptor	Endocrinology
2,3-Dinor-11beta-prostaglandin F2alpha (2,3-Dinor-11β-PGF2α) is a metabolite of PGD2. Urinary excretion of 2,3-Dinor-11beta-prostaglandin F2alpha is increased in patients with mast cell activation disease (MCAD) and has been used as a marker of increased PGD2 levels. 2,3-Dinor-11beta-prostaglandin F2alpha levels are also increased in the urine of patients with asthma and are positively correlated with impaired lung function.

HY-125327

YM-543	Others	Metabolic Disease
YM-543 is a selective SGLT2 inhibitor that effectively reduces hyperglycemia in type 2 diabetic mice through increased urinary glucose excretion. YM-543 demonstrates potent inhibition of both mouse and human SGLT2 activities at nanomolar concentrations. YM-543, when administered orally, significantly improves glucose tolerance in diabetic models and sustains its effects for over 12 hours. YM-543, in combination with other antidiabetic agents like rosiglitazone or metformin, enhances the therapeutic effects on diabetic symptoms. YM-543 does not affect blood glucose levels in normal mice, indicating its specificity for diabetic conditions.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113409

3-Hydroxyisovaleric acid	Structural Classification Classification of Application Fields Source classification Endocrine diseases Metabolic Disease Endogenous metabolite Immune System Disorder Microorganisms Ketones, Aldehydes, Acids Disease markers Nervous System Disorder Disease Research Fields Cardiovascular System Disorder Cancer	Endogenous Metabolite
3-Hydroxyisovaleric acid is a normal endogenous metabolite excreted in the urine. The urinary excretion of 3-hydroxyisovaleric acid is early and sensitive indicator of biotin deficiency .

HY-76199

trans-4-Hydroxycyclohexanecarboxylic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Bacterial
trans-4-Hydroxycyclohexanecarboxylic acid is a substrate for cyclohexanecarboxylic acid production. trans-4-Hydroxycyclohexanecarboxylic acid is the by-product of intestinal bacterial metabolism via urinary excretion .

HY-113420

11-Dehydro-thromboxane B2	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
11-Dehydro-thromboxane B2 is a platelet hemagglutinin. Thromboxane inhibition was assessed by urinary excretion levels of 11-Dehydro-thromboxane B2. 11-Dehydro-thromboxane B2 can be used in the study of atherosclerotic thrombosis .

HY-113377A

L-Glyceric acid sodium	Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
L-Glyceric acid sodium is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid sodium can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid sodium excretion to distinguish PH1 from PH2 .

HY-113329

Guanidinoethyl sulfonate Taurocyamine	Structural Classification Natural Products Other disease Classification of Application Fields Disease markers Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Guanidinoethyl sulfonate (Taurocyamine), a transport antagonist of taurine, induces much urinary taurine excretion with a resulting decrease in the tissue taurine content and readily produces taurine-deficient fetal rats in pregnant rats . Guanidinoethyl sulfonate, a structural analogue of taurine, acts as a competitive inhibitor of taurine transport .

HY-113465

Leukotriene E4 LTE4	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Endogenous Metabolite
Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.

HY-113377

L-Glyceric acid	Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
L-Glyceric acid is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid excretion to distinguish PH1 from PH2 .

Cat. No.	Product Name	Chemical Structure

HY-113465S

Leukotriene E4-d5
Leukotriene E4-d₅ is the deuterium labeled Leukotriene E4. Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.

HY-113420S2

11-Dehydro-thromboxane B2-13C5
11-Dehydro-thromboxane B2- ¹³C₅ is ¹³C labeled 11-Dehydro-thromboxane B2 (HY-113420). 11-Dehydro-thromboxane B2 is a platelet hemagglutinin. Thromboxane inhibition was assessed by urinary excretion levels of 11-Dehydro-thromboxane B2. 11-Dehydro-thromboxane B2 can be used in the study of atherosclerotic thrombosis .

Cat. No.	Product Name		Classification

HY-132613

Lumasiran sodium		siRNAs
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

urinary excretion

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products